Description
Humacyte is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale.
The Company uses its technology platform to engineer and manufacture human acellular vessels (HAVs). The HAVs are designed to be implanted into any patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio (or cabinet) of HAVs with varying diameters and lengths.
The HAV cabinet offers treatment solution in various clinical areas within vascular repair, reconstruction and replacement market, including trauma, AV access for hemodialysis, peripheral arterial disease (PAD), and coronary artery bypass grafting (CABG). In addition, the Company develops HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
